logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme Gains Approval From Brazil For Monoclonal Antibody Lemtrada

Genzyme Corp., a biotechnology company and an unit of Sanofi (SNY), Friday said ANVISA, Brazil's national health surveillance agency, has approved Lemtrada for the treatment of patients with relapsing forms of multiple sclerosis to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

While Mexico, Canada, Australia and EU have approved Lemtrada, FDA has rejected the compound, a decision Genzyme intends to appeal in the future.

The development of the compound included two randomized Phase 3 studies, as well as an ongoing study. The first study, CARE-MS I, compared treatment using Lemtrada with high-dose subcutaneous interferon beta-1a (Rebif) in patients with RRMS who had active disease or were new to treatment. The second study, CARE-MS II, involved patients who had relapsed while on prior therapy.

In CARE-MS I, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, said the company. The company also said that in CARE-MS II, Lemtrada was significantly more effective than interferon beta-1a at reducing annualized relapse rates, and accumulation of disability was significantly slowed in patients given Lemtrada versus interferon beta-1a.

The side-effects of Lemtrada include infusion-associated reactions, infections (upper respiratory tract and urinary tract), lymphopenia and leukopenia. Autoimmune conditions and serious infections can occur in patients receiving Lemtrada.

The first course of Lemtrada is administered through IV on five consecutive days, and the second course is administered on three consecutive days, 12 months later.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Teens and young adults now find Instagram and Snapchat more attractive than Facebook, a new study by eMarketer revealed. The report also suggested that for the first time, Snapchat might overtake Facebook in the U.S. by gaining a marketshare of 40.8 percent in social network. A new survey has shown that a majority of parents as well as teens agree that texting or use of cell phones are the biggest distraction to teen drivers. The survey also found that risky driving behavior seems to run in the family. The 2017 Family Safe Driving Report was released by EverQuote Inc., a venture-backed online insurance marketplace. Less than two months after its debut on the New York Stock Exchange, embattled meal-kit delivery company Blue Apron Holdings Inc. has been hit with multiple shareholder lawsuits for its "misleading" and "untrue" statements in its IPO prospectus. The various lawsuits mirror each other in their allegations against Blue Apron, its CEO, CFO, directors and the underwriters of its IPO.
comments powered by Disqus
Follow RTT